Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry
Patients with NAC had worse prognosis, possibly due to unadjusted confounders. Although the availability of immune checkpoint inhibitors (ICIs) limits the clinical impact, the result could provide supplemental insights for treatment decisions in patients who are not candidates for ICIs.
Authors
- Takanori Ishida
- Hirofumi Suwa
- Tomoe Taji (ORCID: https://orcid.org/0000-0002-1309-2763)
- Shigehira Saji (ORCID: https://orcid.org/0000-0002-6732-8030)
- Yuki Kataoka (ORCID: https://orcid.org/0000-0001-7982-5213)
- Hiraku Kumamaru (ORCID: https://orcid.org/0000-0002-9759-6191)
- Naruto Taira (ORCID: https://orcid.org/0000-0003-4266-1117)
- Hiroshi Ishiguro (ORCID: https://orcid.org/0000-0002-0805-7648)
- Kotaro Iijima (ORCID: https://orcid.org/0000-0003-2847-5297)
Institutions
- Kansai Medical University (JP)
- Fukushima Medical University (JP)
- Kawasaki Medical School (JP)
- Tohoku University (JP)
- Kyoto University (JP)
- Hyogo Prefectural Amagasaki General Medical Center (JP)
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- The Breast
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1016/j.breast.2025.104460
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japanese Breast Cancer Society